These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15188842)

  • 1. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers.
    Stiefel U; Paterson DL; Pultz NJ; Gordon SM; Aron DC; Donskey CJ
    Infect Control Hosp Epidemiol; 2004 May; 25(5):380-3. PubMed ID: 15188842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.
    Paterson DL; Muto CA; Ndirangu M; Linden PK; Potoski BA; Capitano B; Bonomo RA; Aron DC; Donskey CJ
    Antimicrob Agents Chemother; 2008 Feb; 52(2):465-9. PubMed ID: 18025111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enterococci.
    Rice LB; Lakticová V; Helfand MS; Hutton-Thomas R
    J Infect Dis; 2004 Dec; 190(12):2162-6. PubMed ID: 15551215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.
    May AK; Melton SM; McGwin G; Cross JM; Moser SA; Rue LW
    Shock; 2000 Sep; 14(3):259-64. PubMed ID: 11028540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.
    Winston LG; Charlebois ED; Pang S; Bangsberg DR; Perdreau-Remington F; Chambers HF
    Am J Infect Control; 2004 Dec; 32(8):462-9. PubMed ID: 15573053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.
    Donskey CJ; Hanrahan JA; Hutton RA; Rice LB
    J Infect Dis; 2000 May; 181(5):1830-3. PubMed ID: 10823795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci.
    Quale J; Landman D; Saurina G; Atwood E; DiTore V; Patel K
    Clin Infect Dis; 1996 Nov; 23(5):1020-5. PubMed ID: 8922796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice.
    Stiefel U; Pultz NJ; Helfand MS; Donskey CJ
    Infect Control Hosp Epidemiol; 2004 May; 25(5):373-9. PubMed ID: 15188841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
    Kundrapu S; Sunkesula VC; Jury LA; Cadnum JL; Nerandzic MM; Musuuza JS; Sethi AK; Donskey CJ
    BMC Infect Dis; 2016 Apr; 16():159. PubMed ID: 27091232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
    Murray PR; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
    Jones RN; Stilwell MG; Rhomberg PR; Sader HS
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins.
    Lautenbach E; LaRosa LA; Marr AM; Nachamkin I; Bilker WB; Fishman NO
    Clin Infect Dis; 2003 Feb; 36(4):440-6. PubMed ID: 12567301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.